Pfizer said on Saturday that its inhaled insulin, Exubera, will be available in the U.S. starting in mid-July.
They also presented new data from studies at the 66th Annual Scientific Sessions of the American Diabetes Association in Washington, D.C.
Although the drug was approved by the FDA in January, the company previously said it would take some time to develop an education program for doctors and patients before putting the drug on the market.
Insider's view: unusual timing, to say the least!
Few, if any, major drug launches happen during holiday seasons. Is there a story here? Is all well between Pfizer and Nektar?
Feel free to get in touch.
No comments:
Post a Comment